inci name ghk-cu ghk cu copper tripeptide 1 Formulation & Manufacturing Expert Guide You will inci name for ghk-cu ghk-cu

Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record

Compound class: synthetic small oligopeptide

Soluble fiber means it can dissolve in water, forming a gel-like material that pulls things through the digestive tract

provider reviews your intake and determines which protocol tier, Foundation (resveratrol), Advanced (GHK-Cu sublingual), or Premium (rapamycin), is appropriate for your individual profile

BPC157 Size: 10MG Guaranteed Quality 24/7 Customer Support Secure Ordering 2-Day Shipping Third Party Tested Batch & Lot Tracking About BPC157 BPC157 research-use catalog item